Listed

Compass Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2020

Filed with the SEC on Mar 5, 2021 and accepted by EDGAR at Mar 5, 2021, 08:28 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2020-01-01 to 2020-12-31$14.9mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2020-01-01 to 2020-12-31−$27.8mus-gaap:OperatingIncomeLoss
Interest expense12 months2020-01-01 to 2020-12-31$908.0kus-gaap:InterestExpense
Income tax12 months2020-01-01 to 2020-12-31$32.0kus-gaap:IncomeTaxExpenseBenefit
Net income12 months2020-01-01 to 2020-12-31−$29.5mus-gaap:NetIncomeLoss
Diluted EPS12 months2020-01-01 to 2020-12-31−$0.96us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2020-01-01 to 2020-12-31−$26.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2020-01-01 to 2020-12-31$106.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-12-31$47.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-12-31$50.2mus-gaap:AssetsCurrent
Total assetsAt period end2020-12-31$51.9mus-gaap:Assets
Current liabilitiesAt period end2020-12-31$10.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-12-31$12.0mus-gaap:Liabilities
Long-term debtAt period end2020-12-31$1.9mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2020-12-31$7.5mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2020-12-31$39.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-21-011110. Last ingested by Listed: Nov 10, 2026, 16:45 ET. Listed shows no prices and gives no investment advice.